cenobamate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
tranquillizers, propanediol and pentanediol derivatives 5355 913088-80-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ontozry
  • cenobamate
  • YKP3089
  • xcopri
The precise mechanism by which cenobamate exerts its therapeutic effects in patients with partial-onset seizures is unknown. Cenobamate has been demonstrated to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the gamma-aminobutyric acid (GABAA) ion channel.
  • Molecular weight: 267.67
  • Formula: C10H10ClN5O2
  • CLOGP: 1.25
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 95.92
  • ALOGS: -2.46
  • ROTB: 5
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
S (Water solubility) 1.70 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ
BA (Bioavailability) 88 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CDK5,EIF2AK3,ERBB2,GRK2,MAPK7,PDK1,PDK2,PDK4,PRKDC 12
kinase-selectivity-class GRK2 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
March 26, 2021 EMA ARVELLE THERAPEUTICS NETHERLANDS B.V.
Nov. 21, 2019 FDA SK LIFE SCIENCE INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 297.82 56.03 108 1478 152521 90474340
Drug interaction 156.83 56.03 82 1504 276371 90350490
Multiple-drug resistance 105.67 56.03 25 1561 7751 90619110
Generalised tonic-clonic seizure 61.23 56.03 23 1563 34880 90591981
Suicidal ideation 56.56 56.03 27 1559 73828 90553033

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 188.91 53.12 83 1110 120478 42499664
Multiple-drug resistance 110.21 53.12 28 1165 7294 42612848
Drug interaction 93.47 53.12 69 1124 266930 42353212
Ataxia 76.07 53.12 25 1168 16100 42604042

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 443.51 49.06 177 2650 221008 110365464
Drug interaction 223.06 49.06 145 2682 500038 110086434
Multiple-drug resistance 215.70 49.06 53 2774 13182 110573290
Somnolence 98.20 49.06 72 2755 297377 110289095
Ataxia 84.50 49.06 31 2796 30077 110556395
Petit mal epilepsy 77.76 49.06 21 2806 7526 110578946
Status epilepticus 68.70 49.06 27 2800 31544 110554928
Drug ineffective 66.09 49.06 129 2698 1520411 109066061
Seizure cluster 64.06 49.06 12 2815 821 110585651
Partial seizures 60.81 49.06 19 2808 11330 110575142
Tonic convulsion 58.67 49.06 14 2813 3060 110583412

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AX25 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Other antiepileptics
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
FDA MoA N0000181004 Sodium Channel Antagonists
FDA MoA N0000182139 Cytochrome P450 2B6 Inhibitors
FDA MoA N0000182140 Cytochrome P450 2C19 Inhibitors
FDA MoA N0000185506 Cytochrome P450 3A4 Inducers
FDA MoA N0000187063 Cytochrome P450 2C8 Inducers
FDA MoA N0000187064 Cytochrome P450 2B6 Inducers
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors
FDA MoA N0000193997 GABA A Receptor Positive Modulators
CHEBI has role CHEBI:35623 anticonvulsant

Related Drugs by ATC class:

N03AX Other antiepileptics 18 drugs
beclamidebrivaracetamcannabidiolcarisbamatefelbamatefenfluramineganaxolonelacosamidelamotriginelevetiracetamperampanelphenacemide show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Partial seizure indication 29753000
Epilepsy having focal-onset seizures indication 84757009 DOID:1826
Genetic short QT syndrome contraindication 698273002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.88 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG XCOPRI SK LIFE N212839 March 10, 2020 RX TABLET ORAL 11654133 June 16, 2039 CO-ADMINISTRATION OF CENOBAMATE WITH PHENOBARBITAL AND/OR PHENYTOIN FOR THE TREATMENT OF PARTIAL ONSET SEIZURES
12.5MG XCOPRI SK LIFE N212839 March 10, 2020 RX TABLET ORAL 11654133 June 16, 2039 CO-ADMINISTRATION OF CENOBAMATE WITH PHENOBARBITAL AND/OR PHENYTOIN FOR THE TREATMENT OF PARTIAL ONSET SEIZURES
150MG XCOPRI SK LIFE N212839 March 10, 2020 RX TABLET ORAL 11654133 June 16, 2039 CO-ADMINISTRATION OF CENOBAMATE WITH PHENOBARBITAL AND/OR PHENYTOIN FOR THE TREATMENT OF PARTIAL ONSET SEIZURES
200MG XCOPRI SK LIFE N212839 March 10, 2020 RX TABLET ORAL 11654133 June 16, 2039 CO-ADMINISTRATION OF CENOBAMATE WITH PHENOBARBITAL AND/OR PHENYTOIN FOR THE TREATMENT OF PARTIAL ONSET SEIZURES
25MG XCOPRI SK LIFE N212839 March 10, 2020 RX TABLET ORAL 11654133 June 16, 2039 CO-ADMINISTRATION OF CENOBAMATE WITH PHENOBARBITAL AND/OR PHENYTOIN FOR THE TREATMENT OF PARTIAL ONSET SEIZURES
50MG XCOPRI SK LIFE N212839 March 10, 2020 RX TABLET ORAL 11654133 June 16, 2039 CO-ADMINISTRATION OF CENOBAMATE WITH PHENOBARBITAL AND/OR PHENYTOIN FOR THE TREATMENT OF PARTIAL ONSET SEIZURES

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Gamma-aminobutyric acid receptor subunit alpha-4 Ion channel ALLOSTERIC MODULATOR EC50 4.38 IUPHAR
Gamma-aminobutyric acid receptor subunit alpha-6 Ion channel ALLOSTERIC MODULATOR EC50 4.24 IUPHAR

External reference:

IDSource
P85X70RZWS UNII
4039272 VANDF
C4550368 UMLSCUI
CHEMBL3989949 ChEMBL_ID
11962412 PUBCHEM_CID
DB06119 DRUGBANK_ID
D11150 KEGG_DRUG
10116 INN_ID
C000654784 MESH_SUPPLEMENTAL_RECORD_UI
10773 IUPHAR_LIGAND_ID
830240007 SNOMEDCT_US
830244003 SNOMEDCT_US
CHEBI:234112 CHEBI
332202 MMSL
38242 MMSL
d09522 MMSL
018214 NDDF
2265690 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Xcopri HUMAN PRESCRIPTION DRUG LABEL 1 71699-025 TABLET, FILM COATED 25 mg ORAL NDA 34 sections
Xcopri HUMAN PRESCRIPTION DRUG LABEL 1 71699-050 TABLET, FILM COATED 50 mg ORAL NDA 34 sections
Xcopri HUMAN PRESCRIPTION DRUG LABEL 1 71699-100 TABLET, FILM COATED 100 mg ORAL NDA 34 sections
Xcopri HUMAN PRESCRIPTION DRUG LABEL 1 71699-150 TABLET, FILM COATED 150 mg ORAL NDA 34 sections
Xcopri HUMAN PRESCRIPTION DRUG LABEL 1 71699-200 TABLET, FILM COATED 200 mg ORAL NDA 34 sections
Xcopri HUMAN PRESCRIPTION DRUG LABEL 1 71699-204 TABLET 12.50 mg ORAL NDA 34 sections